CALM-IT

This study involves the use of JZP541 as a treatment for agitation in Alzheimer’s disease. Agitation in Alzheimer’s disease is most commonly treated with a group of drugs called atypical antipsychotics, but not everyone benefits from them and there have been concerns about their safety. JZP541 is a non-psychoactive compound in cannabis (or marijuana). The purpose of this study is to learn more about how effective JZP541 is in treating different systems associated with agitation in patients with AD. To do this, some of the participants in this study will get JZP541, followed by placebo, and others will receive placebo, followed by JZP541. There will be 12 study visits and 8 telephone visits in total over 23 weeks.